Gender, Age
Item
Male or female between, and including, 6-12 weeks (42 to 90 days) of age at the time of the first vaccination.
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Compliance to requirements of the protocol
Item
Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits).
boolean
C0525058 (UMLS CUI [1,1])
C0030551 (UMLS CUI [1,2])
C0525058 (UMLS CUI [2,1])
C0023226 (UMLS CUI [2,2])
Informed consent
Item
Written informed consent obtained from the parent or guardian of the subject.
boolean
C0021430 (UMLS CUI [1,1])
C0030551 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2,1])
C0023226 (UMLS CUI [2,2])
No Disease (medical history and clinical examination)
Item
Free of obvious health problems as established by medical history and clinical examination before entering into the study.
boolean
C3898900 (UMLS CUI [1,1])
C0262926 (UMLS CUI [1,2])
C3898900 (UMLS CUI [2,1])
C1456356 (UMLS CUI [2,2])
Born after a gestation period
Item
Born after a gestation period (between 36 and 42 weeks).
boolean
C3814420 (UMLS CUI [1])
Other investigational drug/vaccine
Item
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period (active phase and 6 months safety follow-up).
boolean
C0205394 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0205394 (UMLS CUI [2,1])
C1517586 (UMLS CUI [2,2])
C0042210 (UMLS CUI [2,3])
Chronic use of Immunosuppressants/ immunemodifying drugs (excluding inhaled/topical steroids)
Item
Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. (For corticosteroids, this will mean prednisone, or equivalent, >= 0.5 mg/kg/day. Inhaled and topical steroids are allowed.)
boolean
C0205191 (UMLS CUI [1,1])
C0021081 (UMLS CUI [1,2])
C0683607 (UMLS CUI [2,1])
C2065041 (UMLS CUI [2,2])
C0683607 (UMLS CUI [3,1])
C3897353 (UMLS CUI [3,2])
Administration of other vaccine
Item
Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before each dose of vaccine(s) and ending 7 days after dose 1 and dose 2 or 1 month after dose 3.
boolean
C2368628 (UMLS CUI [1,1])
C1518384 (UMLS CUI [1,2])
C0750503 (UMLS CUI [1,3])
C0042196 (UMLS CUI [1,4])
Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, Bacillus Calmette-Guérin (BCG), and/or S. pneumoniae (excepted hepatitis B vaccination)
Item
Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, Bacillus Calmette-Guérin (BCG), and/or S. pneumoniae with the exception of vaccines where the first dose can be given within the first two weeks of life according to the national recommendations (for example hepatitis B vaccination)
boolean
C0205156 (UMLS CUI [1,1])
C0012559 (UMLS CUI [1,2])
C0205156 (UMLS CUI [2,1])
C0199809 (UMLS CUI [2,2])
C0205156 (UMLS CUI [3,1])
C0199818 (UMLS CUI [3,2])
C0205156 (UMLS CUI [4,1])
C0004886 (UMLS CUI [4,2])
C0205156 (UMLS CUI [5,1])
C0042196 (UMLS CUI [5,2])
C0038410 (UMLS CUI [5,3])
C0332300 (UMLS CUI [6,1])
C0474232 (UMLS CUI [6,2])
History of/intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, Haemophilus influenzae type b
Item
History of or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b diseases.
boolean
C0262926 (UMLS CUI [1,1])
C0012546 (UMLS CUI [1,2])
C0277557 (UMLS CUI [2,1])
C0012546 (UMLS CUI [2,2])
C0262926 (UMLS CUI [3,1])
C0039614 (UMLS CUI [3,2])
C0277557 (UMLS CUI [4,1])
C0039614 (UMLS CUI [4,2])
C0262926 (UMLS CUI [5,1])
C0043167 (UMLS CUI [5,2])
C0277557 (UMLS CUI [6,1])
C0043167 (UMLS CUI [6,2])
C0262926 (UMLS CUI [7,1])
C0019163 (UMLS CUI [7,2])
C0277557 (UMLS CUI [8,1])
C0019163 (UMLS CUI [8,2])
C0262926 (UMLS CUI [9,1])
C0032371 (UMLS CUI [9,2])
C0277557 (UMLS CUI [10,1])
C0032371 (UMLS CUI [10,2])
C0262926 (UMLS CUI [11,1])
C0121772 (UMLS CUI [11,2])
C0277557 (UMLS CUI [12,1])
C0121772 (UMLS CUI [12,2])
Allergic disease/reactions to vaccine component (including diphtheria toxoid)
Item
History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, including diphtheria toxoid.
boolean
C1527304 (UMLS CUI [1,1])
C0042210 (UMLS CUI [1,2])
C1705248 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C0042210 (UMLS CUI [2,2])
C1705248 (UMLS CUI [2,3])
C0332257 (UMLS CUI [3,1])
C0012551 (UMLS CUI [3,2])
History of seizures/neurological disease
Item
History of seizures or neurological disease.
boolean
C0262926 (UMLS CUI [1,1])
C0036572 (UMLS CUI [1,2])
C0262926 (UMLS CUI [2,1])
C0027765 (UMLS CUI [2,2])
Acute disease
Item
Acute disease at the time of enrolment.
boolean
C0001314 (UMLS CUI [1])
Immunosuppression (based on medical hisytory and physical examination)
Item
Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination (no laboratory testing required).
boolean
C4048329 (UMLS CUI [1,1])
C0262926 (UMLS CUI [1,2])
C4048329 (UMLS CUI [2,1])
C0031809 (UMLS CUI [2,2])
C0021051 (UMLS CUI [3,1])
C0262926 (UMLS CUI [3,2])
C0021051 (UMLS CUI [4,1])
C0031809 (UMLS CUI [4,2])
Family history of congenital or hereditary immunodeficiency
Item
A family history of congenital or hereditary immunodeficiency.
boolean
C0241889 (UMLS CUI [1,1])
C0853602 (UMLS CUI [1,2])
C0241889 (UMLS CUI [2,1])
C0439660 (UMLS CUI [2,2])
C0021051 (UMLS CUI [2,3])
Major congenital defects/serious chronic illness
Item
Major congenital defects or serious chronic illness.
boolean
C0000768 (UMLS CUI [1,1])
C0205164 (UMLS CUI [1,2])
C0008679 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
Immunoglobulins, blood products
Item
Administration of immunoglobulins and/or any blood products since birth or planned administration during the active phase of the study.
boolean
C0021027 (UMLS CUI [1])
C0456388 (UMLS CUI [2])